Published in Inflamm Bowel Dis on November 01, 2000
Increased expression of interleukin 17 in inflammatory bowel disease. Gut (2003) 9.16
Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol (2009) 1.51
Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.28
Rho activation regulates CXCL12 chemokine stimulated actin rearrangement and restitution in model intestinal epithelia. Lab Invest (2007) 1.18
Synthesis and anti-inflammatory activities of mono-carbonyl analogues of curcumin. Bioorg Med Chem Lett (2008) 1.16
RNA aptamers selected against the receptor activator of NF-kappaB acquire general affinity to proteins of the tumor necrosis factor receptor family. Nucleic Acids Res (2004) 1.12
Inhibition of LPS-induced production of inflammatory factors in the macrophages by mono-carbonyl analogues of curcumin. J Cell Mol Med (2009) 1.10
Hyperosmotic stress induces nuclear factor-kappaB activation and interleukin-8 production in human intestinal epithelial cells. Am J Pathol (2002) 1.08
Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease. Theranostics (2013) 1.06
CCR6 regulation of the actin cytoskeleton orchestrates human beta defensin-2- and CCL20-mediated restitution of colonic epithelial cells. J Biol Chem (2009) 0.98
The p38 mitogen-activated protein kinase regulates interleukin-1beta-induced IL-8 expression via an effect on the IL-8 promoter in intestinal epithelial cells. Immunology (2003) 0.92
Targeted intestinal epithelial deletion of the chemokine receptor CXCR4 reveals important roles for extracellular-regulated kinase-1/2 in restitution. Lab Invest (2011) 0.90
Enhanced recruitment of CX3CR1+ T cells by mucosal endothelial cell-derived fractalkine in inflammatory bowel disease. Gastroenterology (2006) 0.90
Unfractionated heparin and new heparin analogues from ascidians (chordate-tunicate) ameliorate colitis in rats. J Biol Chem (2009) 0.88
Therapeutic and prophylactic thalidomide in TNBS-induced colitis: synergistic effects on TNF-alpha, IL-12 and VEGF production. World J Gastroenterol (2007) 0.86
Chemokines in inflammatory bowel disease. J Clin Pathol (2005) 0.85
Polymorphism of monocyte chemoattractant protein 1 in Crohn's disease. Int J Colorectal Dis (2003) 0.84
The gut microbiome in intestinal fibrosis: environmental protector or provocateur? Sci Transl Med (2013) 0.82
Hyperbaric oxygen treatment for inflammatory bowel disease: a systematic review and analysis. Med Gas Res (2012) 0.80
Regulation of alpha1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells. Clin Exp Immunol (2002) 0.78
Polymorphisms of the macrophage inflammatory protein 1 alpha and ApoE genes are associated with ulcerative colitis. Int J Colorectal Dis (2008) 0.77
Curcuma longa extract exerts a myorelaxant effect on the ileum and colon in a mouse experimental colitis model, independent of the anti-inflammatory effect. PLoS One (2012) 0.77
CCR9 Is a Key Regulator of Early Phases of Allergic Airway Inflammation. Mediators Inflamm (2016) 0.75
Autologous adipose tissue-derived stem cells for the treatment of complex perianal fistulas not associated with Crohn's disease: a phase II clinical trial for safety and efficacy. Tech Coloproctol (2017) 0.75
Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology (2000) 3.90
Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology (1996) 3.08
Analysis of intestinal lymphocytes in mouse colitis mediated by transfer of CD4+, CD45RBhigh T cells to SCID recipients. J Immunol (1997) 3.05
Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology (2000) 2.99
Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med (2000) 2.93
Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses. Gastroenterology (1991) 2.93
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis (2001) 2.80
Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease. Gut (2000) 2.71
Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut (2000) 2.47
Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology (1998) 2.38
Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol (2001) 2.36
Familial empirical risks for inflammatory bowel disease: differences between Jews and non-Jews. Gut (1993) 2.35
A role for TNF-alpha and mucosal T helper-1 cytokines in the pathogenesis of Crohn's disease. J Immunol (1997) 2.28
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther (2010) 2.20
An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology (1999) 2.16
Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology (2000) 2.10
Distinct associations of HLA class II genes with inflammatory bowel disease. Gastroenterology (1993) 2.10
Neutrophil cytoplasmic antibodies: a link between primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1991) 2.06
Long-term outcomes of thalidomide in refractory Crohn's disease. Aliment Pharmacol Ther (2014) 2.06
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med (1991) 2.03
The role of thymus-expressed chemokine and its receptor CCR9 on lymphocytes in the regional specialization of the mucosal immune system. J Immunol (2000) 2.03
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther (2001) 1.94
Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology (1999) 1.84
Identification of a prodromal period in Crohn's disease but not ulcerative colitis. Am J Gastroenterol (2000) 1.77
An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis (2001) 1.77
A genome-wide search identifies potential new susceptibility loci for Crohn's disease. Inflamm Bowel Dis (1999) 1.74
Divergent induction of apoptosis and IL-8 secretion in HT-29 cells in response to TNF-alpha and ligation of Fas antigen. J Immunol (1995) 1.70
Neutrophil autoantibodies in ulcerative colitis: familial aggregation and genetic heterogeneity. Gastroenterology (1992) 1.67
Association of antineutrophil cytoplasmic antibodies with resistance to treatment of left-sided ulcerative colitis: results of a pilot study. Mayo Clin Proc (1996) 1.61
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology (2001) 1.57
Triggered human mucosal T cells release tumour necrosis factor-alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol (1991) 1.55
Role of anaerobic bacteria in spontaneous peritonitis of cirrhosis: report of two cases and review of the literature. Am J Med (1977) 1.53
Characterization of the cytolytic reaction mechanism of the human natural killer (NK) lymphocyte: resolution into binding, programming, and killer cell-independent steps. J Immunol (1982) 1.51
Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun (2000) 1.49
CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohn's disease. Gastroenterology (2001) 1.48
Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis (2001) 1.44
Antineutrophil cytoplasmic antibody subtypes in children and adolescents after ileal pouch-anal anastomosis for ulcerative colitis. J Pediatr Gastroenterol Nutr (1998) 1.44
Lack of an association between polymorphisms of the T-cell receptor alpha-chain and ulcerative colitis. Gastroenterology (1989) 1.42
Ulcerative colitis: a genetically heterogeneous disorder defined by genetic (HLA class II) and subclinical (antineutrophil cytoplasmic antibodies) markers. J Clin Invest (1993) 1.37
Sulfasalazine-induced exacerbation of ulcerative colitis. N Engl J Med (1982) 1.32
Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect Immun (1999) 1.28
Immunologic mechanisms in intestinal diseases. Ann Intern Med (1987) 1.23
Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther (2007) 1.23
Spontaneous peritonitis of cirrhosis due to Campylobacter fetus. Gastroenterology (1976) 1.19
ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn's disease. Gastroenterology (2001) 1.18
Intercellular adhesion molecule 1 gene associations with immunologic subsets of inflammatory bowel disease. Gastroenterology (1995) 1.18
Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol (2001) 1.17
Regulation of immune responses of the intestinal mucosa. Crit Rev Immunol (1996) 1.16
Definition of a "trigger" stage in the NK cytolytic reaction sequence by a monoclonal antibody to the glycoprotein T-200. J Immunol (1983) 1.11
Identification of human natural killer soluble cytotoxic factors (NKCF) derived from NK-enriched lymphocyte populations: specificity of generation and killing. J Immunol (1983) 1.10
Linkage of Crohn's disease to the major histocompatibility complex region is detected by multiple non-parametric analyses. Gut (1999) 1.09
Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol (1995) 1.06
Tumor necrosis factor microsatellites define a Crohn's disease-associated haplotype on chromosome 6. Gastroenterology (1996) 1.06
Expression of a novel autoantibody defined by the VH3-15 gene in inflammatory bowel disease and Campylobacter jejuni enterocolitis. J Immunol (1994) 1.00
Current theories on the causes of inflammatory bowel disease. Gastroenterol Clin North Am (1999) 1.00
Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism. Aliment Pharmacol Ther (2012) 0.99
Identification of histone H1 as a cognate antigen of the ulcerative colitis-associated marker antibody pANCA. J Autoimmun (2000) 0.99
Increased neutrophil receptors for and response to the proinflammatory bacterial peptide formyl-methionyl-leucyl-phenylalanine in Crohn's disease. Gastroenterology (1989) 0.98
Measurement of tumor necrosis factor alpha mRNA in small numbers of cells by quantitative polymerase chain reaction. Reg Immunol (1993) 0.96
HLA class II haplotype associations with inflammatory bowel disease in Jewish (Ashkenazi) and non-Jewish caucasian populations. Hum Immunol (2000) 0.96
Fas activates the JNK pathway in human colonic epithelial cells: lack of a direct role in apoptosis. Am J Physiol (1999) 0.94
Cytokine-based therapies in inflammatory bowel disease. Curr Opin Gastroenterol (1999) 0.93
Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun (2001) 0.91
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis. Am J Gastroenterol (2000) 0.90
Mucosa-specific targets for regulation of IFN-gamma expression: lamina propria T cells use different cis-elements than peripheral blood T cells to regulate transactivation of IFN-gamma expression. J Immunol (2000) 0.90
The "lazy" NK cells of Chediak-Higashi syndrome. J Immunol (1983) 0.90
Pouchitis disease course after orthotopic liver transplantation in patients with primary sclerosing cholangitis and an ileal pouch-anal anastomosis. Am J Gastroenterol (1995) 0.89
Additional evidence of linkage between Crohn's disease and a putative locus on chromosome 12. Genet Med (2001) 0.88
Studies on the mechanism of the human natural killer cell lethal hit: analysis of the mechanism of protease inhibition of the lethal hit. J Immunol (1983) 0.87
Defective memory B cell formation in patients with inflammatory bowel disease following tetanus toxoid booster immunization. J Clin Lab Immunol (1987) 0.86
Immunomodulator therapy in inflammatory bowel disease. Dig Dis Sci (1994) 0.86
Serologic testing in inflammatory bowel disease: its value in indeterminate colitis. Curr Gastroenterol Rep (1999) 0.85
Enhanced neutrophil chemiluminescence in familial Mediterranean fever. J Clin Immunol (1988) 0.83
TNF-alpha antagonists for the treatment of Crohn's disease. Expert Opin Pharmacother (2000) 0.83
Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr (1994) 0.82
Crohn's ileitis after liver transplantation from a living related donor with Crohn's disease. Gut (2004) 0.82
Immunobiological and immunochemical aspects of the T-200 family of glycoproteins. Mol Immunol (1984) 0.82
Phage display cloning and characterization of an immunogenetic marker (perinuclear anti-neutrophil cytoplasmic antibody) in ulcerative colitis. J Immunol (1996) 0.82
Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion. J Immunol (1998) 0.82
Morbidity of subtotal colectomy in patients with severe ulcerative colitis unresponsive to cyclosporin. Dis Colon Rectum (1995) 0.81
Campylobacter fetus associated with pulmonary abscess and empyema. Chest (1977) 0.81
Active target cell processes, possibly involving receptor-mediated endocytosis, are critical for expression of cytotoxicity by natural killer cell-derived cytolytic factor. Cell Immunol (1986) 0.81
Efficacy of mycophenolate mofetil in patients failing 6-mercaptopurine or azathioprine therapy for Crohn's disease. Inflamm Bowel Dis (2000) 0.81
Sequential substages of natural killer cell-derived cytolytic factor (NKCF)-mediated cytolysis as defined by glutaraldehyde modulation of the target cell. J Immunol (1984) 0.81
K562 killing by K, IL 2-responsive NK, and T cells involves different effector cell post-binding trigger mechanisms. J Immunol (1986) 0.81
CD161 DEFINES EFFECTOR T CELLS THAT EXPRESS LIGHT AND RESPOND TO TL1A-DR3 SIGNALING. Eur J Microbiol Immunol (Bp) (2011) 0.81
The search for pathogenic antigens in ulcerative colitis. Gastroenterology (1998) 0.80
Analysis of sequential substages of the natural killer cell lethal hit. Adv Exp Med Biol (1985) 0.80
A soluble factor produced by lamina propria mononuclear cells is required for TNF-alpha enhancement of IFN-gamma production by T cells. J Immunol (1999) 0.79
Definition of a secondary target cell trigger during natural killer cell cytotoxicity: possible role of phospholipase A2. Cell Immunol (1987) 0.79
Role of the CD45 (T-200) molecule in anti-CD3-triggered T cell-mediated cytotoxicity. Cell Immunol (1988) 0.79
Mast cell and neuroendocrine cytoplasmic autoantigen(s) detected by monoclonal pANCA antibodies. Clin Immunol (2000) 0.78
Bone marrow modulaton of spontaneous killer cellular cytotoxicity (SKCC) induction. J Clin Lab Immunol (1980) 0.78
Inhibition of human natural killing by heterologous and monoclonal antibodies. J Immunol (1982) 0.78